Arca
Skip to content
Tools
Tools

CD86: T-lymphocyte activation antigen CD86

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an important role in T-lymphocyte activation.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 1

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CD86, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide

Approved2

  • Abatacept
  • Belatacept

Phase 30

    Phase 20

      Phase 10

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        AbataceptApprovedBristol-Myers SquibbProtein or peptideInhibitorT-lymphocyte activation antigen CD86 inhibitor51—
        BelataceptApprovedBristol-Myers SquibbProtein or peptideInhibitorT-lymphocyte activation antigen CD86 inhibitor15Boxed warning

        Open Trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
        A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male ParticipantsAbataceptPhase 1Not yet recruitingDr. Reddy's Laboratories Limited, India2026-08-04
        PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCTAbataceptPhase 1 / Phase 2RecruitingNorthwell Health2026-06-30
        Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseAbataceptPhase 2RecruitingSt. Jude Children's Research Hospital2026-06-01
        Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsAbataceptPhase 1 / Phase 2RecruitingNational Heart, Lung, and Blood Institute (NHLBI)2026-05-20
        Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaAbataceptPhase 1RecruitingNational Cancer Institute (NCI)2026-02-05
        Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesAbataceptPhase 2 / Phase 3RecruitingFederal Research Institute of Pediatric Hematology, Oncology and Immunology2026-01-26
        Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorAbataceptPhase 2RecruitingSt. Petersburg State Pavlov Medical University2025-11-20
        Study of COYA 302 for the Treatment of ALSAbataceptPhase 2 / Phase 3Active, not recruitingCoya Therapeutics2025-09-09
        Treatment of Antibody-Mediated Rejection (ABMR) With CarBelBelataceptPhase 1RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)2025-04-09
        Belatacept in Heart TransplantationBelataceptPhase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)2024-06-27
        Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only ImmunosuppressionBelataceptNot applicableEnrolling by invitationUniversity of Texas Southwestern Medical Center2024-03-29
        Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)BelataceptPhase 2 / Phase 3Not yet recruitingUniversity Hospital, Rouen2024-03-04
        Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>BelataceptPhase 4RecruitingUniversity Hospital, Rouen2024-03-04
        Advancing Transplantation Outcomes in ChildrenBelataceptPhase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)2023-09-28
        Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow TherapyBelataceptPhase 1Enrolling by invitationStanford University2023-08-03
        Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.Belatacept—Active, not recruitingUniversity Hospital, Rouen2023-02-01

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        Immune system disorder
        0.46
        Hypothyroidism
        0.40
        Cancer
        0.39
        Kidney transplant
        0.39
        Neurodegenerative disease
        0.36
        Temporal arteritis
        0.34
        Lymphoid neoplasm
        0.33
        Heart transplant rejection
        0.31

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364156, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P42081, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.